The International Myeloma Foundation Welcomes Dr. Stephen L. Houff to the IMF Board of Directors Read more about The International Myeloma Foundation Welcomes Dr. Stephen L. Houff to the IMF Board of DirectorsAdd new comment
FDA Grants Fast Track Designation for Trispecific Antibody IBI3003 as Treatment for Relapsed/Refractory Multiple Myeloma Read more about FDA Grants Fast Track Designation for Trispecific Antibody IBI3003 as Treatment for Relapsed/Refractory Multiple MyelomaAdd new comment
FDA Approves Darzalex Faspro in Combination with Bortezomib, Lenalidomide, and Dexamethasone (VRd) for the Treatment of Transplant-Ineligible Newly Diagnosed Multiple Myeloma Read more about FDA Approves Darzalex Faspro in Combination with Bortezomib, Lenalidomide, and Dexamethasone (VRd) for the Treatment of Transplant-Ineligible Newly Diagnosed Multiple Myeloma Add new comment
FDA Releases Draft Guidance for MRD and CR as Endpoints to Support Accelerated Approval for Myeloma Drugs Read more about FDA Releases Draft Guidance for MRD and CR as Endpoints to Support Accelerated Approval for Myeloma Drugs Add new comment
January 2026 – Myeloma News from the Journals Read more about January 2026 – Myeloma News from the JournalsAdd new comment
European Medicines Agency Receives Type II Variation Application from Johnson & Johnson for Tecvayli (teclistamab) in Combination with Subcutaneous Darzalex (daratumumab) for the Treatment of RRMM Read more about European Medicines Agency Receives Type II Variation Application from Johnson & Johnson for Tecvayli (teclistamab) in Combination with Subcutaneous Darzalex (daratumumab) for the Treatment of RRMMAdd new comment
2025 IMF Nurse Leadership Board Annual Meeting Read more about 2025 IMF Nurse Leadership Board Annual Meeting Add new comment
December 2025 – Myeloma News from the Journals Read more about December 2025 – Myeloma News from the JournalsAdd new comment
U.S. FDA Awards National Priority Voucher to sBLA Application for Tecvayli and Darzalex Faspro Combination Based on MajesTEC-3 Trial Results Read more about U.S. FDA Awards National Priority Voucher to sBLA Application for Tecvayli and Darzalex Faspro Combination Based on MajesTEC-3 Trial ResultsAdd new comment
U.S. FDA Grants Breakthrough Therapy Designation for Tecvayli plus Darzalex Faspro as a Second Line for Patients with Relapsed/Refractory Multiple Myeloma Read more about U.S. FDA Grants Breakthrough Therapy Designation for Tecvayli plus Darzalex Faspro as a Second Line for Patients with Relapsed/Refractory Multiple MyelomaAdd new comment
